BrainSpec offers a web-based platform that utilizes Magnetic Resonance Spectroscopy (MRS) to provide a non-invasive "virtual biopsy" of brain tissue, measuring metabolite concentrations for accurate diagnosis of brain disorders. This technology enables clinicians and researchers to interpret brain chemistry data efficiently, facilitating the diagnosis of conditions such as brain tumors and Alzheimer's disease without the need for surgical procedures.
Funding
$30.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing and monitoring brain disorders often requires invasive surgical biopsies to analyze brain tissue composition. Traditional methods lack the ability to detect subtle biochemical changes in the brain before structural changes occur, hindering early and accurate diagnosis. The interpretation of Magnetic Resonance Spectroscopy (MRS) data can be complex and time-consuming, limiting its accessibility for clinicians and researchers.
Solution
BrainSpec offers a web-based software platform that leverages Magnetic Resonance Spectroscopy (MRS) to provide a non-invasive "virtual biopsy" of brain tissue. The platform combines a post-processing backend based on a linear combinations model with a user-friendly web interface, ensuring precise analysis and ease of use. BrainSpec streamlines MRS interpretation by comparing patient data to a database of reference brain chemistry, making it as straightforward as analyzing routine blood test results. This technology enables clinicians and researchers to efficiently interpret brain chemistry data, facilitating the diagnosis and monitoring of conditions such as brain tumors, Alzheimer’s disease, Multiple Sclerosis, Traumatic Brain Injury, Parkinson’s Disease, Epilepsy, Schizophrenia, and Hypoxic Ischemic Encephalopathy without the need for surgical procedures. The platform supports cross-vendor compatibility, allowing users to analyze data acquired from standard MRI machines.
Target Audience
The primary users are clinicians and researchers in neurology, radiology, and oncology who require non-invasive methods for diagnosing and monitoring brain disorders.
Features
- Web-based platform for processing and analyzing Magnetic Resonance Spectroscopy (MRS) data.
- Post-processing backend based on a linear combinations model for accurate metabolite quantification.
- User-friendly web interface for efficient case processing and streamlined interpretation.
- Database of reference brain chemistry for use in clinical applications.
- Extended database of diseased brain chemistry for use in a research context.
- Automatic reporting functionality for generating concise summaries of findings.
- Cloud-based processing ensures access to the most up-to-date algorithms and reference data.
- Cross-vendor support for data acquired from standard MRI machines.